CSF1R and hepatocellular carcinoma: Throughout regorafenib–nivolumab treatment, classical monocyte subsets exhibited significantly increased expression levels of a regorafenib-responsive gene set derived from an HCC model12 and of a gene signature representing CSF1R knockout, only among long-term responders and not early progressors (Fig. 4h,i).